Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Alector, Inc (ALEC) operate in?
Alector, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Alector, Inc (ALEC) current stock price?
As of the latest data, Alector, Inc stock price is $2.15, with a previous close of $2.09. Alector, Inc gained $0.06 in the last trading session, representing a 2.87% increase.
What is Alector, Inc (ALEC) current market capitalization?
Alector, Inc market cap is approximately 240.06 million.
What is Alector, Inc (ALEC) Earnings Per Share (EPS)?
The trailing EPS is -$1.16, and the forward EPS is -$0.70.
What is Alector, Inc (ALEC) EBITDA?
Alector, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -18.73 million.
Does Alector, Inc (ALEC) pay dividends?
No. Alector, Inc does not pay a dividend.
How did Alector, Inc (ALEC) perform in its most recent earnings report?
In the last report (June 30, 2026), Alector, Inc posted an EPS surprise of 12.5% and a revenue surprise of 93.78%.
What is Alector, Inc (ALEC) beta (volatility) score?
Alector, Inc has a beta of 0.580, indicating lower volatility than the overall market.
